| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.4 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.4 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.059 | 0.4 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.4 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.4 |
| mRNA | JQ-1:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.4 |